Is 3D printing of structures for implantation in the human body using bioresorbable polymers to be considered a type of bioprinting? In a way, it is and it can bring significant healthcare benefits sooner than parts printed using actual cells will be able to. Along the lines of: “why change it if you can fix it?” That’s what an ETH Zurich research team did, using DLP 3D printing to produce a new type of bioresorbable airway stent that could greatly simplify the future treatment of upper airway obstruction.
Narrowing of the trachea or the main bronchi due to injury or illness can end very badly. If patients get too little oxygen, they risk suffocating and often need medical help as quickly as possible. Surgeons insert stents made of medically usable silicone or metal as a way of treating these patients. Although they quickly bring relief, the implants also have disadvantages: Metal stents have to be removed surgically with some effort, which is a burden for the patients, while silicone stents often migrate away from the insertion site. The reason for this is that the implants are not adapted to a patient’s anatomy.
An ETH Zurich research team, composed of members of the Complex Materials and Drug Formulation and Delivery groups, has now developed an airway stent together with researchers from the University Hospital Zurich and the University of Zurich; it is tailored to patients and bioresorbable, (i.e., it gradually dissolves after implantation). These stents are manufactured using a 3D printing process known as digital light processing (DLP) and light-sensitive resins specially adapted for this purpose.
First, the researchers create a computer tomography image of a specific section of the airways. Based on this, they develop a digital 3D model of the stent. The data is then transferred to the DLP printer, which produces the customized stent layer by layer.
In the past, a bioresorbable airway stent has been produced – and successfully implanted in humans – using SLS 3D printing technology and polycaprolactone power. DLP technology using biodegradable materials, however, usually produces stiff and brittle objects. The ETH researchers developed a special resin that becomes elastic after light exposure. This resin is based on two different macromonomers.
The material properties of the object produced with it can be controlled by the length (molecular weight) of the macromonomers used and by their mixing ratio, as the researchers show in their latest study in Science Advances. Since the newly developed resin is too viscous at room temperature, the researchers had to process it at temperatures of 70 to 90 degrees Celsius.
The researchers produced several resins with different monomers and tested the prototypes they made from them to see whether the material is cell-compatible and biodegradable. They also tested the prototypes for elasticity and for mechanical stress such as compression and tension. Finally, the scientists used the material with the desired properties to make stents, which were tested on rabbits.
Inserting the stents also required a special instrument, as the 3D printed objects have to be delivered folded. The implants cannot be kinked or squeezed in the wrong direction and they have to unfold perfectly at their site of deployment.
The researchers included gold in the stent’s structure in order to facilitate the use of medical imaging to track its location during insertion. This makes the stent more robust but does not change its tolerability.
The tests on the rabbits conducted by the research group of Daniel Franzen, Senior Physician at the Department of Pneumology at the University Hospital Zurich, and the Vetsuisse faculty were successful. The researchers were able to show that the implants are biocompatible and that they are absorbed by the body after six to seven weeks. Ten weeks after implantation, the stent was no longer visible on X-ray images. In addition, the inserted stents generally did not move from their insertion site.
“This promising development opens up prospects for the rapid production of customized medical implants and devices that need to be very precise, elastic and degradable in the body,” said Jean-Christophe Leroux, Professor of Drug Formulation and Delivery at ETH Zurich. Further research will focus on making the insertion of the stents as gentle as possible.
Furthermore, the processes are to be designed in such a way that production is possible at the point of use, or at least would involve short supply chains. The process is still on a laboratory scale. “However, producing such stents on a large scale is a complex undertaking that we still need to study better,” says André Studart, head of the Complex Materials Group at ETH. However, he says the technique can be transferred relatively easily to similar medical applications. “It is hopefully only a matter of time before our solution finds its way into the clinic,” concluded the professor.